XML 57 R20.htm IDEA: XBRL DOCUMENT
v3.23.2

Revenue (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2023
Revenue [Abstract] |
Revenue recognized | Revenue is presented by type, and net of deductions in the table below. The Group’s accounting policies for revenue and such deductions are disclosed in the consolidated financial statements of the Group for the year ended December 31, 2022.
|  | For the three months ended June 30, |  |  | For the six months ended June 30, |
|  | 2023 £’000 |  |  | 2022 £’000 |  |  | 2023 £’000 |  |  | 2022 £’000 |
Product revenue, net |  |  | 45,514 |  |  |  | 23,992 |  |  |  | 87,566 |  |  |  | 31,674 |
Pre-product revenue, net |  |  | — |  |  |  | 3,708 |  |  |  | — |  |  |  | 6,537 |
Total revenue from sale of therapies |  |  | 45,514 |  |  |  | 27,700 |  |  |  | 87,566 |  |  |  | 38,211 |
Collaboration revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Eli Lilly |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 7,361 |
Genentech |  |  | 2,250 |  |  |  | 4,302 |  |  |  | 4,739 |  |  |  | 8,904 |
Total collaboration revenue |  |  | 2,250 |  |  |  | 4,302 |  |  |  | 4,739 |  |  |  | 16,265 |
Total revenue |  |  | 47,764 |  |  |  | 32,002 |  |  |  | 92,305 |  |  |  | 54,476 |
Eli Lilly and Genentech are based in the United States. Net product revenue from the sale of KIMMTRAK, and net pre-product revenue from the sale of tebentafusp as part of a compassionate use and early access program are presented by region based on the location of the customer below.
|  | For the three months ended June 30, |  |  | For the six months ended June 30, |
|  | 2023 £’000 |  |  | 2022 £’000 |  |  | 2023 £’000 |  |  | 2022 £’000 |
United States |  |  | 32,812 |  |  |  | 18,137 |  |  |  | 62,345 |  |  |  | 25,819 |
Europe |  |  | 12,189 |  |  |  | 9,560 |  |  |  | 24,517 |  |  |  | 12,389 |
Rest of World |  |  | 513 |  |  |  | 3 |  |  |  | 704 |  |  |  | 3 |
Total revenue from sale of therapies |  |  | 45,514 |  |  |  | 27,700 |  |  |  | 87,566 |  |  |  | 38,211 |

X
- Definition The disclosure of operating segments. [Refer: Operating segments [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2023-01-01 -Paragraph 23 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_DisclosureOfOperatingSegmentsExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | ifrs-full_RevenueAbstract
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration